Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.
about
PAI-1 and atherothrombosis.Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditionsObesity, haemostasis and the fibrinolytic system.Management of the insulin resistance syndrome.Insulin resistance and polycystic ovary syndrome.Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome.Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.PAI-1 and diabetes: a journey from the bench to the bedside.Pathobiology and cell interactions of platelets in diabetes.Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1.Pivotal role of tissue plasminogen activator in the mechanism of action of electroconvulsive therapy.A Forkhead/winged helix-related transcription factor mediates insulin-increased plasminogen activator inhibitor-1 gene transcription.Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells.Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription.Is diabetes a hypercoagulable state? A critical appraisal.Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications.Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes.Identification of a 251-bp fragment of the PAI-1 gene promoter that mediates the ethanol-induced suppression of PAI-1 expression.Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes.Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp.Induction of PAI-1 expression by tumor necrosis factor alpha in endothelial cells is mediated by its responsive element located in the 4G/5G site.The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus.The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes.
P2860
Q33989347-5D49536C-7CC1-4C77-A606-4F71036A98F3Q34217461-41EB390D-A190-48D1-807D-46DA8DE66D0CQ34743382-B9F06FCF-1D7D-49C5-BF9E-5D480378D26EQ35087365-6A8426C4-F590-42F3-8F1F-AD84E27557D5Q35087405-EF41C468-7918-49EE-A938-A037B17B0C16Q35582120-B82C51DE-8DE8-4C1A-960D-0C65CD41B78AQ35936644-F791A9F4-97D6-4B3E-85AB-382FDA8D2BF1Q36228964-9F6CDAB2-E893-4CA9-92D8-ACB855A116FEQ36249561-FF2705CB-305E-4108-9DBB-803F939F672FQ36320564-02583E9B-FF69-42A8-8082-5A784A31500FQ37369762-98C35D2D-E9FE-4224-BEC8-C8E373C509C4Q38151373-E2D0B07B-5CAE-418D-8642-A07221EBCC15Q38290766-56BA022A-F189-4AF8-8A1A-4548963AF6E8Q38338004-3595A02A-80DC-4A4D-813A-7C5E6A4E6E99Q38342702-5B7DA3D4-A1BA-40CE-84DA-E4289A2C32C7Q38409740-076A9E3B-0BE1-4133-B4AE-68D02731408FQ40331436-8DBF1F78-0FE0-454E-957A-073006C4C2ABQ41156168-4E1770A9-7873-47CC-86AA-FD7DD03914CFQ41457652-A85362D4-FC1D-4F20-B109-851B5E42C585Q42825179-20E0D6CB-ABFF-4B9A-BB42-885DC28366A8Q43616528-CB62E60C-A747-4E69-92E2-4DA1FA8DD29EQ44563272-32CF1893-48F8-4D12-A298-FB23ADCA5C99Q46415645-0FE32321-73DC-4718-85B2-105F4B07E33DQ46798284-28D079ED-1798-4436-B6B9-D71F68777932Q46917480-C7AD3918-68EE-4407-9FDA-653FE7C99379Q54085828-42DD615E-0763-4647-B1A3-6CC2B7776662
P2860
Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Augmentation of the synthesis ...... k factor for vascular disease.
@en
Augmentation of the synthesis ...... k factor for vascular disease.
@nl
type
label
Augmentation of the synthesis ...... k factor for vascular disease.
@en
Augmentation of the synthesis ...... k factor for vascular disease.
@nl
prefLabel
Augmentation of the synthesis ...... k factor for vascular disease.
@en
Augmentation of the synthesis ...... k factor for vascular disease.
@nl
P2093
P356
P1433
P1476
Augmentation of the synthesis ...... k factor for vascular disease.
@en
P2093
P304
P356
10.1161/01.CIR.89.1.321
P407
P577
1994-01-01T00:00:00Z